These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951 [TBL] [Abstract][Full Text] [Related]
3. Personalizing ovarian cancer screening. Goozner M J Natl Cancer Inst; 2010 Aug; 102(15):1112-3. PubMed ID: 20668268 [No Abstract] [Full Text] [Related]
4. Listen for the "whispering disease". Learn the subtle signs and symptoms of ovarian cancer. Martin VR Nurs Manage; 2000 Apr; 31(4):30-1. PubMed ID: 15127636 [No Abstract] [Full Text] [Related]
5. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer. Jacobs I Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S22-7. PubMed ID: 7835805 [No Abstract] [Full Text] [Related]
6. A step forward for two-step screening for ovarian cancer. Hensley ML J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556 [No Abstract] [Full Text] [Related]
7. Circulating tumour markers in ovarian tumours. von Schlippe M; Rustin GJ Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987 [TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer screening: a look at the evidence. Fields MM; Chevlen E Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731 [TBL] [Abstract][Full Text] [Related]
9. [Mass-screening for ovarian cancer]. Sato S; Higuchi T; Yokoyama Y; Sakamoto T Nihon Rinsho; 2004 Oct; 62 Suppl 10():601-4. PubMed ID: 15535316 [No Abstract] [Full Text] [Related]
10. [Early detection and preoperative diagnosis of ovarian carcinoma]. Kainz C Wien Med Wochenschr; 1996; 146(1-2):2-7. PubMed ID: 8835487 [TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer screening. American College of Radiology. ACR Appropriateness Criteria. Böhm-Vélez M; Mendelson E; Bree R; Finberg H; Fishman EK; Hricak H; Laing F; Sartoris D; Thurmond A; Goldstein S Radiology; 2000 Jun; 215 Suppl():861-71. PubMed ID: 11037511 [No Abstract] [Full Text] [Related]
12. CA-125: a biomarker put to the test. Schmidt C J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262 [No Abstract] [Full Text] [Related]
13. How appropriate are the american college of radiology appropriateness criteria for ovarian cancer screening. Dubinsky TJ Ultrasound Q; 2010 Dec; 26(4):225-6. PubMed ID: 21084937 [No Abstract] [Full Text] [Related]
15. Progress report on ovarian cancer screening. Scientists are making headway in detecting ovarian cancer at an earlier stage. Harv Womens Health Watch; 2010 Apr; 17(8):1-3. PubMed ID: 20506601 [No Abstract] [Full Text] [Related]
16. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases]. Petignat P; Vajda D; Obrist R Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132 [TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer screening: a primary care guide. Thompson SD Lippincotts Prim Care Pract; 1998; 2(3):244-50. PubMed ID: 9644439 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic markers for early detection of ovarian cancer. Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665 [TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795 [TBL] [Abstract][Full Text] [Related]
20. Screening for gynecologic malignancies: A continuing responsibility. Runowicz CD; Fields AL Surg Oncol Clin N Am; 1999 Oct; 8(4):703-23, vii. PubMed ID: 10452936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]